This study is in progress, not accepting new patients
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UC Davis UCLA UCSF
- Dates
- study startedstudy ends around
- Principal Investigator
- by Varun Monga (ucsf)
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Varun Monga (ucsf)
Dr. Varun Monga is a Board Certified Medical Oncologist who serves as an Clinical Associate Professor of Medicine in the Division of Hematology and Oncology. He joined UCSF Medical Center in 2023 and he provides patient care services limited to UCSF Sarcoma Center and Cancer Clinical Trials and Investigational Treatments Center.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Prelude Therapeutics
- ID
- NCT05639751
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- About 135 people participating
- Last Updated